Tivozanib hydrochloride bulk supplier for pharma manufacturers

Tivozanib Hydrochloride 0.89 mg, 1.34 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 0.89 mg, 1.34 mg

Reference Brands: Fotivda (USA/EU)

Tivozanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma (RCC). It works by blocking the VEGF receptors involved in tumor angiogenesis, thereby slowing or stopping the growth of cancer cells.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Tivozanib Hydrochloride? List it or send an offer →

Product Description:

Tivozanib inhibits all three VEGF receptors with unusually high selectivity and picomolar potency. Selectivity is its rationale: the earlier antiangiogenic kinase inhibitors hit dozens of unrelated kinases, and the resulting fatigue, hand-foot syndrome and diarrhoea forced dose reductions that left VEGF signalling incompletely suppressed. A cleaner drug can be dosed to full target coverage, so hypertension — the on-target class effect — dominates its profile rather than off-target toxicity.

It is used for relapsed or refractory advanced renal cell carcinoma in patients who have received at least two prior systemic therapies, taken once daily for three weeks of each four-week cycle. Hypertension is expected and needs antihypertensive treatment prepared before starting rather than after it appears. Dysphonia, fatigue, diarrhoea and hypothyroidism occur. Arterial and venous thromboembolic events, haemorrhage, proteinuria and impaired wound healing follow the class, and treatment is interrupted around surgery.

Sourcing notes. Originator product, on patent. The two capsule strengths are the full and reduced doses, so both are needed for a treatment course. The unusual decimal strengths reflect the free base content and should be transcribed exactly in any quotation. Oral capsules, room temperature.

How Tivozanib Hydrochloride is supplied today, and licensing ahead of patent expiry

Tivozanib Hydrochloride is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Tivozanib Hydrochloride, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Tivozanib Hydrochloride supply →

Back to Listing

Frequently Asked Questions

Tivozanib hydrochloride is used for the treatment of advanced renal cell carcinoma (RCC) in adults, particularly in cases where the disease has progressed following other cancer therapies.

Tivozanib hydrochloride is made from the active ingredient Tivozanib, a potent and selective inhibitor of VEGF receptors, combined with hydrochloride to form its salt.

The trade name of Tivozanib hydrochloride is Fotivda.

Tivozanib hydrochloride is manufactured by AVEO Oncology and EUSA Pharma.

The generic name is Tivozanib hydrochloride.

The brand name is Fotivda.

Tivozanib hydrochloride is manufactured in countries including the United States, the United Kingdom, and Ireland by AVEO Oncology and EUSA Pharma for global cancer treatment markets.

Fotivda (Tivozanib) is developed and sold by AVEO Oncology (LG Chem) in the US, and by Recordati in Europe. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.